In 2009, it was suggested by researchers from the National Birth Defects Prevention Study that nitrofurans and sulfonamides, antibiotics commonly used for the treatment of urinary tract infections (UTIs), may increase the risk of birth defects when taken during the first trimester.
In 2009, it was suggested by researchers from the National Birth Defects Prevention Study that nitrofurans and sulfonamides, antibiotics commonly used for the treatment of urinary tract infections (UTIs), may increase the risk of birth defects when taken during the first trimester. Despite this warning, the American College of Obstetricians and Gynecologists, in a new Committee Opinion, have deemed these two antibiotics appropriate to use when there is no suitable alternative, even in the first trimester.1 In the second and third trimesters, when the potential risk for nitrofurans and sulfonamides to cause birth defects is less, these agents should be considered first-line treatment for UTIs.
Reference
1. American College of Obstetricians and Gynecologists. Committee opinion no. 494: sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol. 2011;117:1484-1485.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More